1:30...My computer couldn't get online during CVH...I think they blocked it..lol..takeaway...stay away until 2010

1:30 down only 13% since last JPM..from Press Release..it has IT'S PIPELINE...CAMBRIDGE, Mass., Jan. 12, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (NasdaqGM:INFI - News), an innovative cancer drug discovery and development company, today reported on its 2008 R&D and business progress, announced its key 2009 objectives, and introduced its I4 2012 goals. Infinity's I4 2012 goals are the four major strategic objectives the company anticipates achieving by the end of 2012. Infinity's key highlights from 2008: * Initiated the RING trial -- an international Phase 3 registration trial of IPI-504 (retaspimycin hydrochloride), its potential first-in-class inhibitor of heat shock protein 90 (Hsp90), in patients with refractory gastrointestinal stromal tumors (GIST); * Expanded both arms of the Phase 2 portion of a study of IPI-504 in patients with non-small cell lung cancer (NSCLC); * Filed two Investigational New Drug (IND) applications and initiated clinical trials with two new innovative molecules: IPI-493, its oral Hsp90 inhibitor, and IPI-926, its Hedgehog pathway inhibitor; * Entered into a global strategic alliance with Purdue Pharma and Mundipharma for the development and commercialization of Infinity's early clinical and discovery pipeline; * Secured full U.S. commercialization rights to its entire oncology portfolio; and * Ended 2008 with capital sufficient to support the company's current operating plan for four years, through 2012. ``2008 was a pivotal year in Infinity's development, and thanks to the tireless commitment of our team of citizen-owners, we delivered tangible results across all areas of our business and science operations,'' stated Steven H. Holtzman, chair and chief executive officer. ``We are poised to achieve our newly announced I4 2012 goals with the strongest financial position in our history, a pipeline of novel drug candidates directed to areas of significant unmet medical need, and the opportunity to build our commercial infrastructure. With 2008 as our foundation, we are more innovative, independent and inspired than ever before to achieve our mission of bringing important new medicines to patients while creating exceptional value for shareholders.'' I4 2012: Infinity has also announced for the first time its ``I4 2012'' goals -- the four major strategic achievements that will distinguish Infinity by 2012: * At least one marketed oncology product, commercialized by Infinity in the U.S. * Three oncology product candidates in global pivotal trials * Five or more product candidates in clinical development * A strong financial profile and exceptional value-creation ``2009 will be an important and active year for Infinity, as we continue aggressively to advance our drug candidates,'' said Adelene Q. Perkins, president and chief business officer. ``Ultimately, we believe shareholder value will be created by executing on our development programs, demonstrating the benefit our drug candidates may provide patients, and marketing our innovative anti-cancer agents in the United States ourselves. We expect our clinical program over the next four years will yield new approaches for the treatment of many types of cancer and enable us to establish a strong commercial presence for Infinity.'' 2009 Key Milestones: * Report Phase 2 results of the study of IPI-504 in NSCLC in mid-2009 * Report preliminary data from the Phase 1b trial of IPI-504 in combination with Taxotere(r) in mid-2009 * Report preliminary data from the Phase 1 clinical trial of IPI-493 oral in the second half of 2009 * Initiate additional clinical trials with its Hsp90 inhibitors, including in HER2+ metastatic breast cancer, in 2009 * Report preclinical data evaluating IPI-926, Infinity's oral Hedgehog pathway inhibitor, in multiple tumor models in mid-2009 * Advance IPI-940, Infinity's novel fatty acid amide hydrolase inhibitor, to IND by the end of 2009 * Maintain a strong financial position with an anticipated net cash burn of $25-35 million and a 2009 year-end cash and investments balance of $122-$132 million, not including any amounts that Infinity may draw under the $50 million line of credit from Purdue Pharma. About Infinity Pharmaceuticals, Inc. Infinity is an innovative cancer drug discovery and development company seeking to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging cancer pathways. Infinity's two most advanced programs in Hsp90 inhibition and Hedgehog signaling pathway inhibition are evidence of its innovative approach to oncology drug discovery and development

2..Robotic Arm..will report in March..but issued this press release..2008 Fourth Quarter Selected Operating Results MAKOplasty Procedure Volume -- During the fourth quarter, 200 MAKOplasty procedures were performed, representing a 26% increase over the third quarter of 2008. A total of 601 MAKOplasty procedures were performed during the 2008 year, compared to 2008 annual guidance of 550 to 600 MAKOplasty procedures, representing a 258% increase from the 2007 year. TGS Sales -- Four TGS units were installed and customer accepted at commercial sites during the 2008 fourth quarter. A total of twelve TGS units were installed and customer accepted at commercial sites in the 2008 year, compared to 2008 annual guidance of ten to eleven units. The total number of commercial TGS sites as of December 31, 2008 was seventeen. ``We are pleased with our selected operating results for the fourth quarter,'' said Maurice R. Ferre, M.D., President and Chief Executive Officer of MAKO. ``The completion of 200 MAKOplasty procedures and the addition of four new commercial sites despite the challenging economic conditions highlight the benefits our surgeons and hospitals recognize from implementing our Tactile Guidance System and offering patients an attractive alternative to total knee replacement.''

2..went to this one..here are notes... Now I am at WOOF...the CEO looks so much more positive then the CVH CEO who looked so sad. WOOF...they have had great success in their lab unit with good margin growth but the economy has hurt them...but the are trying to maintain margins. They have 467 hospitals...normal client spends about 135-150 dollars...the landscape is changing...people are getting more indepth treatment for pets..before it was just Neuter and shots. Hospitals are not ression proof but better then CVH...lol...they stil have positive comps...managing labor(not pay raises) cutting payroll hours, Sound Tech is their Imaging Unit..Digital Radiology is 57% of the unit...23% Ultrasound...they have 845 units in place. Almost a full room. Cash 95M...OMG guys I just asked a question in the Q and A about pet ownership decline which was the basis of recent downgrades...CEO said it was such a marginal amount that it should not be a factor...I am cool...wonder if my question will come out on their website..normally you go to a breakout session...but CEO was done early and is taking Q and A in the room. BTW this is the FIRST company that is giving Swag...WOOF HATS...

2:30..per Adam F..Jeff P. read my list of important clinical trials for the first half of 2009 and says that I forget to mention Viropharma (VPHM - commentary - Cramer's Take) and its drug Camvia. Sure enough, Jeff is correct. Viropharma is running a phase III study of Camvia (also known as maribavir) as a treatment for the prevention of cytomegalovirus infection in stem-cell transplant patients, with results expected in the first quarter of 2009 ..per Motley Fool..ViroPharma Not many companies can brag of gains in their stock in 2008, but ViroPharma joined other biotech stocks like Gilead Sciences (Nasdaq: GILD) and Amgen (Nasdaq: AMGN) in this class. The key is plenty of cash flowing into the firm's coffers, making ViroPharma a cash-rich small cap that many CAPS members believe has solid potential. The company is expected to expand its cash-generating ways, thanks to its recent acquisition of Lev Pharmaceuticals, which will bring Cinryze to market alongside its current drug, Vancocin. At this point, more than 97% of the 1,180 CAPS members rating ViroPharma think the company can continue to buck the down market and outperform the S&P...

2:30..from Press Release..here is their Pipeline..2009 Milestones and Clinical Activities In 2009, XenoPort or its collaborators expect to advance the development of XenoPort’s product candidates as follows: GSK submitted a new drug application, or NDA, with the Food and Drug Administration, or FDA, for Solzira™ (known as XP13512 outside the United States) as a potential treatment for moderate-to-severe primary restless legs syndrome, or RLS, on January 9. XenoPort expects to receive milestone payments of $23 million in the aggregate from GSK and Astellas Pharma Inc., which are associated with the acceptance by the FDA of the NDA. GSK has previously disclosed that it expects results from the following trials in 2009: A Phase 2 clinical trial of Solzira in patients with painful diabetic neuropathy. Two Phase 2 clinical trials of Solzira in patients with post-herpetic neuralgia. GSK is conducting a Phase 2 clinical trial of Solzira as a potential prophylactic treatment for migraine headaches that was initiated in August 2008, and a polysomnography clinical trial of Solzira in RLS patients that was initiated in October 2008. Astellas is conducting a Phase 2 clinical trial of XP13512 in RLS patients in Japan that completed enrollment in October 2008. XenoPort expects to report results from a Phase 2 clinical trial of XP19986 in spinal cord injury patients with spasticity by mid-year. XenoPort expects to complete an exploratory safety study of XP19986 in patients with acute back spasms of neuromuscular origin by year end. The first subject was enrolled in this trial in December 2008. XenoPort expects to commence in the second half of this year a Phase 2 clinical trial of XP19986 as a potential treatment for subjects with gastroesophageal reflux disease, or GERD, who are incomplete responders to proton pump inhibitors. XenoPort expects to complete a Phase 1 clinical trial in healthy subjects designed to assess the pharmacokinetics and safety/tolerability of two new formulations of XP21279 compared to oral L-dopa in the first quarter. XenoPort expects to commence a multiple-dose clinical trial exploring the safety, tolerability and pharmacokinetics of XP21279 in Parkinson’s disease patients. Separately, Xanodyne Pharmaceuticals, Inc. expects to file an NDA with the FDA on XP12B, its modified-release tranexamic acid product candidate for the reduction of menstrual blood loss in women with menorrhagia, or excessive menstrual bleeding. Pursuant to the terms of its exclusive licensing agreement with Xanodyne, XenoPort would be eligible to receive escalating single-digit royalties on any sales of XP12B. Ronald W. Barrett, Ph.D., chief executive officer of XenoPort, stated, “2009 will be an important year for XenoPort. We were pleased to announce that GSK re-filed the Solzira NDA and we look forward to working with GSK to provide this promising product candidate to patients who are suffering from RLS. We believe additional data that will become available in 2009 will reveal the potential of Solzira in other indications. Coupled with $40 million in proceeds from our recent registered direct financing, we believe our existing cash plus expected milestones will take us well into 2011. With a possible regulatory action from the FDA for the Solzira NDA and multiple Phase 2 trials in new indications reading out for both Solzira and XP19986 by the end of 2009, we believe that the company is poised for an exciting year.” Financial Guidance XenoPort announced that it expects the net use of cash for 2009 to be in the range of $55 million to $65 million (net use of cash is the difference between the balances of cash and cash equivalents plus short-term investments at 12/31/09 and 12/31/08). This guidance includes expected milestones under its existing collaboration agreements with GSK, Astellas and Xanodyne. The 2009 net use of cash guidance further assumes the suspension of the preclinical development program on XP20925, its Transported Prodrug of propofol, and certain other preclinical activities. XenoPort also announced a provision from its agreement with GSK that has the effect of reducing the expenditure of cash in 2009 if XenoPort exercises its option to co-promote Solzira and participate in a profit-share arrangement. During the period after the co-promotion option is exercised and prior to the launch of Solzira, the cash payments to GSK representing XenoPort’s share of any loss would be deferred and would be repayable following the launch of Solzira. As a result, the foregoing net use of cash guidance for 2009 is not expected to change if XenoPort elects to exercise the co-promotion option under the GSK agreement. About XenoPort XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body’s natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. XenoPort is developing its lead product candidate in partnership with Astellas Pharma Inc. and GSK. GSK has filed with the FDA an NDA for Solzira for the treatment of RLS. XenoPort’s product candidates are also being studied for the potential treatment of GERD, migraine headaches, neuropathic pain, spasticity related to spinal cord injury, acute back spasms and Parkinson’s disease

2:30..they are having problems with Rambus Hedge Fund trying to replace their board members...here is their pr..Mr. Milinazzo stated, “We are especially pleased to reiterate our fourth quarter revenue guidance despite approximately $3-$4 million of negative foreign currency impact. Additionally, though Blackstone’s fourth quarter 2008 revenue was lower than the prior year, it increased sequentially from the third quarter. For the full year 2009 we are forecasting a year-over-year increase in Blackstone revenue of approximately 8%-12%. This increase reflects the estimated impact of a number of planned new product introductions including our new Firebird™ pedicle screw system and Trinity® Evolution, a stem cell-based allograft developed in collaboration with the Musculoskeletal Transplant Foundation.” A live audio webcast of the presentation will be available on the company’s website at www.orthofix.com. About Orthofix International, N.V. Orthofix International N.V., a global medical device company, offers a broad line of minimally invasive surgical, as well as non-surgical, products for the spine, orthopedic, and sports medicine market sectors that address the lifelong bone-and-joint health needs of patients of all ages, helping them achieve a more active and mobile lifestyle. Orthofix’s products are widely distributed around the world to orthopedic surgeons, hospitals and patients via Orthofix’s sales representatives and its subsidiaries, including Breg, Inc. and Blackstone Medical, Inc. In addition, Orthofix is collaborating in R&D partnerships with leading institutions such as the Musculoskeletal Transplant Foundation, the Orthopedic Research and Education Foundation, the Cleveland Clinic Foundation, and the National Osteoporosis Institute

2:30..from a recent downgrade at Yahoo finance..When inVentiv reported its third-quarter results in November, the company said it was gaining new business, but results were being hurt because clients were cutting their budgets and postponing marketing campaigns. Windley said there are fewer opportunities for drug marketing because the Food and Drug Administration isn't approving many new products, and the loss of a contract with Johnson & Johnson will hurt the business. About 30 percent of inVentiv's third-quarter revenue came from the communications business. In a telephone interview, inVentiv Chief Financial Officer David Bassin said the pace of FDA approvals has decreased, but inVentiv is succeeding compared with its competitors. He said it's not clear how much drug company spending will change in 2009. "I don't think anybody's predicting 20 percent growth, I don't think anybody's predicting 20 percent shrinkage," he said. The Somerset, N.J., company said the inVentiv Clinical unit experienced "temporary softening in its staffing business" in the third quarter. But Windley said demand is going to slow down for an extended period, with revenue growth slowing to a single-digit pace and possibly declining. In past years, he said, contract research organizations were overwhelmed by demand from drug companies, which business to inVentiv and other companies. But demand for research isn't growing as fast as it had been.